Investment Rationale
Amanta Healthcare Limited presents a classic inflexion-point setup. The company is a fully integrated sterile liquid manufacturer — India’s only dedicated manufacturer of two-port IV fluid containers using Random Co-Polymer Polypropylene technology — and has recently commissioned two capacity expansion lines: a new SteriPort (LVP) line that will nearly double flagship capacity from 6.6 crore to ~12 crore bottles per year (₹90 crore capex), and a new SVP line expanding small volume parenteral capacity from 20.9 crore to 31.7 crore units per year (₹30 crore capex).
IPO capex has not yet contributed a single rupee to reported results, meaning the real earnings story begins from Q1 FY27 onwards.
Together, these two expansions are expected to deliver ~₹150 crore of incremental annual revenue at steady state, with EBITDA margins expanding to 26–27% (from ~21% today), driven entirely by operating leverage on new capacity commissioned at near-zero incremental fixed cost. A solar captive power plant further adds ₹9 crore of annual EBITDA with a sub-4-year payback. The business combines a differentiated, defensible product with a well-timed capacity and improving post-IPO balance sheet trajectory.
Company Overview
Amanta Healthcare Limited is a sterile liquid pharmaceutical manufacturer incorporated in 1994, listed on NSE/BSE in September 2025, raising 126 crores entirely from fresh issue. It operates a single facility in Hariyala, Kheda, Gujarat, housing seven manufacturing lines across two technology platforms: Aseptic Blow-Fill-Seal (ABFS) for conventional containers and Injection Stretch Blow Moulding (ISBM) for its proprietary SteriPort format.
The business manufactures Large Volume Parenterals (LVPs) and Small Volume Parenterals (SVPs) across six therapeutic segments — IV Fluid Therapy (63% of revenue), Formulations (17%), Diluents & Injectables (9%), Respiratory Care (5%), Irrigation Solutions (5%), and Ophthalmics (2%). Fill volumes range from 2ml to 1,000ml across multiple closure systems, serving everything from routine saline infusions to oncology drug delivery and respiratory nebulisation.
Revenue is distributed across three channels — a domestic branded business through 320+ distributors, an export business spanning 21 countries across 120 registered jurisdictions, and a product partnering business manufacturing for third-party pharma companies on a cost-plus basis. The domestic-export split stands at approximately 68:32.
The Core Differentiator: SteriPort
Before understanding SteriPort, it helps to understand what a two-port IV actually solves. A standard IV bag has one port — fluid in, nothing else. A two-port container adds a second entry point, allowing a drug to be administered into the same line simultaneously — no separate injection, no second bag. In high-acuity settings like oncology, ICU, and post-surgical care, this distinction is clinically meaningful: lower infection risk, simpler administration, and precise drug dosing in a single setup
SteriPort is India’s first ISBM-technology two-port IV fluid container manufactured from Random Co-Polymer Polypropylene. It accounts for ~44% of total revenue and is the primary driver of growth. No other Indian company operates dedicated capacity for two-port IV containers — all competitors (Fresenius, Otsuka, B. Braun, Aculife) use polyethylene and share lines between single-port and two-port production. Amanta holds an estimated 30–35% market share in the two-port system with zero dedicated competition.
The company commissioned formal academic research through a university’s Engineering and Pharmaceutical departments — protocols, stability studies, videography, and photography all documented — establishing the following:
The mechanism is straightforward: PE is a low-density, highly permeable material. It allows oxygen ingress into the container, which triggers oxidation — one of the primary degradation pathways for pharmaceutical compounds. The industry already acknowledges this flaw: PE-based respule manufacturers wrap their products in aluminium foil and fill them with nitrogen to prevent oxidation. PP eliminates this problem at the container level.
The sterilisation gap is equally consequential. At 109°C — the maximum PE can withstand — absolute terminal sterilisation is not achieved. SteriPort, being sterilised at 121°C, meets the global pharmacopoeia standard precisely. In oncology, transplant, and ICU settings, this is not a marginal difference — it is the clinical rationale for physician preference.
The distinction between expiry and compatibility is important: both PE and PP products carry the same 3-year shelf life for their base solutions (e.g., normal saline). The difference becomes evident when active pharmaceutical ingredients—particularly cytotoxics—are added to the bag. Normal saline does not react with PE; anti-cancer drugs do. This is why oncologists, intensivists, and anaesthetists specifically prefer PP-based containers.
Financials
-
Revenue has grown from ₹171 crore (FY21) to ₹275 crore (FY25), with the trajectory interrupted in FY25 (-1.8%) due to deliberate inventory rationalisation rather than demand weakness — 9M FY26 at ₹211 crore annualises to ~₹290+ crore, confirming the underlying growth trajectory is intact.
-
EBITDA margins have remained structurally stable in a tight 20–23% band across five years despite significant swings in raw material costs and inventory cycles, confirming that the business has a predictable and defensible cost structure at the operating level.
-
Gross margins appear volatile (60–79% across years) but this is largely a presentation artifact — driven by inventory liquidation in FY24 and a PP granule price spike in FY23 rather than any fundamental change in product economics. The underlying gross margin normalises to ~65% across the cycle.
-
Finance costs tell the most important story in this P&L — declining from ₹49 crore (FY22) to ₹16.5 crore (9M FY26), they have released ₹32+ crore of annual cash that previously went entirely to lenders. This single line item is the primary driver of PAT expansion from -₹19 crore (FY21) to ₹9.4 crore (9M FY26) — and it continues to improve.
-
Amanta’s balance sheet peaked at 33.6× debt-to-equity in FY21 with negative reserves — the residue of a near-insolvency that culminated in a negotiated debt settlement with KKR and BOI AXA, where lenders accepted a 36% haircut on outstanding obligations.
-
Debt has declined steadily from ₹235 crore (FY21) to ₹186 crore (H1 FY26) entirely through operating cash flows, with no asset sales or equity-funded repayments,a particularly meaningful achievement given finance costs consumed 50–80% of EBITDA through much of this period.
-
The IPO in September 2025 strengthened the equity base — net worth doubled from ₹97 crore to ₹211 crore — but was structured purely as a capex raise; the ₹102 crore cash on the H1 FY26 balance sheet is ring-fenced IPO proceeds that will convert into fixed assets as the SteriPort and SVP expansions are commissioned through FY27.
-
As capex is deployed, net fixed assets are expected to grow from ₹210 crore to ~₹330 crore, while continued operational debt repayment brings total borrowings toward ₹150 crore by FY27 — a debt-to-equity trajectory that would have been unimaginable five years ago.
-
Working capital has remained disciplined through the cycle — trade receivables have stayed within a ₹45–54 crore band over five years despite 60%+ revenue growth.
Growth Strategy: Three Levers
Lever 1: SteriPort LVP Expansion — Q1 FY27 (Primary)
This is the primary growth lever, and its economics are compelling: the new line is being added inside the existing plant, which means zero incremental fixed overhead. All revenue from the additional ~5.4 crore bottles flows through the existing cost structure. The asset-light nature of this expansion is the key reason for the disproportionate margin uplift — incremental EBITDA margin on the new capacity is estimated well above the current blended level.
Importantly, the demand side is not speculative. Two-port IV fluid demand is growing faster than the overall market (which itself grows 8–10% annually), driven by conversion from conventional single-port systems. Two-port currently accounts for only 15–20% of total IV fluid demand, a structurally undersupplied category, and Amanta is the only player with dedicated capacity for it. Competitors would need to replace existing PE lines with PP lines, absorbing significant capital and operational disruption, before they could meaningfully compete.
Lever 2: SVP Expansion — Q4 FY27 (January 2027)
The SVP line is strategically positioned as a high-margin product platform rather than a commoditised infusion line, with Amanta’s respiratory segment at its core — specifically nebulisation solutions (respules), where the company holds the #2 position in Indian exports (Cipla being the market leader). This is a meaningful competitive foothold in a regulatory-moated, high-margin category that provides an established commercial and filing foundation to ramp the new line. Initial revenue contribution will be conservative given that export registrations proceed on a per-country basis, typically taking six months to one and a half years per jurisdiction — but this is a timing lag, not a structural constraint. The real earnings inflection from the SVP expansion arrives in FY28, once the registration pipeline clears across key markets.
Lever 3: Solar Captive Power Plant — Q1 FY27
At current electricity costs for a sterile manufacturing facility, the savings are material and recurring. The ₹9 crore annual EBITDA contribution from the solar plant alone represents ~15% uplift on the FY25 EBITDA base. Combined with the SteriPort expansion, total EBITDA in FY27 is guided at ~₹105 crore — nearly 1.7× FY25 levels.
Projected Financials
-
Revenue scales from ₹275 crore (FY25) to ₹480 crore (FY28E) — a 75% increase in three years driven entirely by capacity, not pricing. FY26 is a transition year at ~₹295 crore; the inflection is FY27 as SteriPort runs full-year and SVP begins contributing.
-
EBITDA nearly doubles from ₹61 crore to ₹130 crore over the same period, with margins expanding from 22% to 27% — the expansion is structural, driven by fixed-cost absorption on incremental revenue that requires no new headcount, no new facility, and no meaningful overhead addition.
-
PAT moves from ₹10 crore (FY25) to ₹66 crore (FY28E) — a 6.6× increase on a 75% revenue jump. The amplification comes from finance costs halving from ₹28 crore to ₹14 crore as debt declines from ₹204 crore to ₹120 crore through operating cash flows alone.
Valuations & Upside Potential
Currently trading at ~6.4× forward earnings with a market capitalisation of ₹381 crore, Amanta is simultaneously commissioning a near-doubling of its flagship LVP capacity, deleveraging its balance sheet at pace, and compounding profits at over 5× through FY27. Given the visibility on both growth levers and the structural decline in finance costs, the business warrants a meaningful earnings multiple, with a reasonable valuation band of 15×–25× FY27E earnings.
Key Risks
-
Raw Material Risk: PP granules are sourced entirely from Italy (77%) and South Korea (23%) with no long-term supply contracts. Any geopolitical escalation — particularly in the Middle East — that spikes crude oil prices leads directly to higher PP granule prices, compressing gross margins. FY23 demonstrated this clearly, with gross margins falling to 60.6% during a period of elevated input costs.
-
SVP Export Registration Lag: Registrations for the new SVP line proceed per-country, per-product — typically 6 to 18 months per jurisdiction. Real earnings contribution from the SVP/respule expansion is therefore back-loaded into FY28, subject to regulatory timing risk outside the company’s control.
-
Criminal Case (Case No. 128/SW/2015): A CDSCO drug inspector filed a criminal case against both the company and Bhavesh Patel (Promoter) personally at the Metropolitan Magistrate Court, Mazgaon, relating to a sterility failure in a 2013 batch supplied to Cama & Albless Hospital. The case has been pending 10+ years with no adverse outcome — but the personal naming of the promoter remains an unresolved overhang.
Disclaimer :
I currently hold shares of the company discussed in this post and therefore my views may be biased.
This write-up is prepared solely for educational and discussion purposes on the ValuePickr forum. It does not constitute investment advice, a recommendation, or an offer to buy or sell any securities under the regulations of the Securities and Exchange Board of India (SEBI).
The information and analysis presented are based on publicly available sources and my personal interpretation, which may be incomplete, inaccurate, or subject to change. I may be completely wrong in my assessment.
I may buy or sell shares of the mentioned company without prior notice. Readers are strongly encouraged to conduct their own independent research (DYOR) and, where necessary, consult a SEBI-registered investment advisor before making any investment decisions.
